Rossari Biotech Posts 4% Dip in Q1 Profit Despite Strong Revenue Growth

Mumbai, July 23, 2025  Specialty chemical manufacturer Rossari Biotech reported a 4% year-on-year decline in its Q1 FY26 net profit, with earnings falling from ₹34.90 crore in Q1 FY25 to ₹33.60 crore in the latest quarter. Despite the dip in profit, the company showcased healthy revenue growth, highlighting resilience amid a challenging economic landscape.

• ? Quarterly Highlights: Revenue up by 11% QoQ to ₹543.72 crore, compared to ₹489.65 crore in the previous quarter.
• Profit before tax dropped marginally by 1.89% to ₹46.10 crore.
• Total expenses rose by 12.5% YoY to ₹499.88 crore.
• Raw material costs increased to ₹334.40 crore (up 17.7% YoY).
• Employee benefits shot up by over 31%, reaching ₹37.46 crore.
• Finance costs climbed by 55% to ₹5.72 crore.

? Leadership Speaks: In a joint statement, Edwar Meneses, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said: “Despite the evolving market dynamics, we’ve delivered a stable performance in Q1 FY26. Growth in our Home, Personal Care & Performance Chemicals (HPPC) and Animal Health & Nutrition (AHN) segments reflects the strength of our strategic focus. While exports saw a slight decline, our domestic business continues to remain strong, thanks to our product mix and operational initiatives.” ? Segment Performance & Future Outlook The HPPC segment registered a solid 16% growth, while AHN followed closely with 12% growth. The company is doubling down on capacity expansion, supply chain enhancements, and targeting high-growth sectors such as agrochemicals, personal care, pharmaceuticals, and oil & gas. With new investments and commissioning underway, Rossari aims to improve operational agility and boost future profitability. ? About Rossari Biotech Headquartered in Mumbai, Rossari Biotech is a leading provider of specialty chemicals across sectors like textiles, home care, personal care, animal nutrition, and industrial performance. The company operates strategically located manufacturing units in Silvassa and Dahej, enabling efficient service to domestic and international markets. Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: [email protected]